In silico analysis of hypoxia activated prodrugs in combination with anti angiogenic therapy through nanocell delivery.

ABSTRACT: Tumour hypoxia is a well-studied phenomenon with implications in cancer progression, treatment resistance, and patient survival. While a clear adverse prognosticator, hypoxia is also a theoretically ideal target for guided drug delivery. This idea has lead to the development of hypoxia-activated prodrugs (HAPs): a class of chemotherapeutics which remain inactive in the body until metabolized within hypoxic regions. In theory, these drugs have the potential for increased tumour selectivity and have therefore been the focus of numerous preclinical studies. Unfortunately, HAPs have had mixed results in clinical trials, necessitating further study in order to harness their therapeutic potential. One possible avenue for the improvement of HAPs is through the selective application of anti angiog

SUBMITTER: Meaney C 

PROVIDER: S-EPMC7282674 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature